
    
      Up to 220 participants will enter an open label extension (OLE) study during which all study
      participants will receive treatment for 12 weeks (84 days). Study participants will be
      followed for 16 weeks (112 days) post treatment-cessation and then the twice daily treatments
      will be re-introduced for the final 8 weeks (56 days).
    
  